No CrossRef data available.
Article contents
Selling Clinical Biospecimens: Guidance for Researchers and Private Industry
Published online by Cambridge University Press: 01 September 2023
Abstract
The recently revised Common Rule requires that donors of biospecimens for research be informed if their specimens might be used for commercial profit. The Common Rule, however, does not apply to sharing or selling de-identified biospecimens that are “leftover” from clinical uses. As a result, many medical researchers remain uncertain of their legal and ethical obligations when a commercial entity expresses interest in these specimens.
Keywords
- Type
- Independent Articles
- Information
- Journal of Law, Medicine & Ethics , Volume 51 , Issue 2: International Collaborations: The Future of Health Care , Summer 2023 , pp. 429 - 436
- Copyright
- © 2023 The Author(s)
References
Faden, R. et al., “An Ethics Framework for a Learning Health Care System: A Departure from Traditional Research Ethics and Clinical Ethics,” Hastings Center Report 43 (2013): S16–S27.CrossRefGoogle Scholar
Id., at S22.Google Scholar
Pollack, A., “Aiming to Push Genomics Forward in New Study,” New York Times January 13, 2014, available at <https://www.nytimes.com/2014/01/13/business/aiming-to-push-genomics-forward-in-new-study.html> (last visited June 15, 2023).+(last+visited+June+15,+2023).>Google Scholar
MyCode scorecard, available at <https://www.geisinger.org/-/media/OneGeisinger/pdfs/ghs/research/mycode/mycode-scorecard.pdf?la=en> (last visited July 14, 2023).+(last+visited+July+14,+2023).>Google Scholar
45 C.F.R §46.116.Google Scholar
Principles and Guidelines for Recipients of NIH Research Grants and Contracts on Obtaining and Disseminating Biomedical Research Resources. 64 FR 72090, December 23, 1999, available at <http://grants.nih.gov/grants/intell-property_64FR72090.pdf> (last visited June 15, 2023).+(last+visited+June+15,+2023).>Google Scholar
Beskow, L.M., “Lessons from HeLa Cells: The Ethics and Policy of Biospecimens,” Annual Review of Genomics and Human Genetics 17 (2016): 395–341; K. Spector-Bagdady, “Reconceptualizing Consent for Direct-to-Consumer Health Services,” American Journal of Law Medicine 41 (2015): 568-616.Google Scholar
Matthew, D.B., “Implementing American Health Care Reform: The Fiduciary Imperative,” Buffalo Law Review 59 (2011): 715–807; M.J. Mehlman, “Why Physicians are Fiduciaries for their Patients,” Indiana Health Law Review 12 (2015): 10-12; P.B. Miller, P. B. and C. Weijer, “Fiduciary Obligation in Clinical Research,” Journal of Law, Medicine & Ethics 34 (2006): 424-440.Google Scholar
Tomlinson, T. and De Vries, R.G., “Human Biospecimens Come from People,” Ethics & Human Research 41 (2019): 22–28.CrossRefGoogle ScholarPubMed
This was part of the reasoning in the Moore case, for example, as well as Greenberg v. Miami Children’s Hospital, 264 F. Supp. 2d 1064, 1075 (S.D. Fla. 2003).Google Scholar
J.L. Roberts, “Genetic Conversion,” (2019), available at <https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3357566> (last visited June 15, 2023).+(last+visited+June+15,+2023).>Google Scholar
Peerenboom v. Perlmutter, No. 2013-CA-015257, at 10 (Fla. Cir. Ct. Apr. 7, 2017).Google Scholar
Kasperbauer, T.J. and Schwartz, P. H., “Genetic Data Aren’t So Special: Causes and Implications of Re-identification,” Hastings Center Report 50 (2020): 30–39.CrossRefGoogle Scholar
Spector-Bagdady, supra note 10.Google Scholar
Lo, B. and Grady, D., “Payments to Physicians: Does the Amount of Money Make a Difference?” JAMA 317 (2017): 1719–1720; P.L. Romain, “Conflicts of Interest in Research: Looking Out for Number One Means Keeping the Primary Interest Front and Center,” Current Reviews in Muscoloskeletal Medicine 8 (2015): 122-127.CrossRefGoogle Scholar
Komesaroff, P.A., Kerridge, I., and Lipworth, W., “Conflicts of Interest: New Thinking, New Processes,” Internal Medicine Journal 49 (2019): 574–577; M. Wiersma, I. Kerridge, and W. Lipworth, “Dangers of Neglecting Non-Financial Conflicts of Interest in Health and Medicine,” Journal of Medical Ethics 44 (2017): 319-322.CrossRefGoogle ScholarPubMed
Racino, B. and Castellano, J., “San Diego VA Confirms Liver Samples Taken from Sick Veterans without their Consent,” inewsource, Feb. 26, 2019, available at <https://inewsource.org/2019/02/26/san-diego-va-liver-study-veterans/> (last visited June 15, 2023).+(last+visited+June+15,+2023).>Google Scholar
Marks, J.H., “Lessons from Corporate Influence in the Opioid Epidemic: Toward a Norm of Separation,” Journal of Bioethical Inquiry 17 (2020): 173–189.CrossRefGoogle Scholar
Caulfield, T. and Ogbogu, U., “The Commercialization of University-Based Research: Balancing Risks and Benefits,” BMC Medical Ethics 16 (2015): 70.CrossRefGoogle ScholarPubMed
Caulfield, T. et al., “A Review of the Key Issues Associated with the Commercialization of Biobanks,” Journal of Law and the Biosciences 1 (2014): 94–110; also see T. Caulfield and B. Murdoch, “Genes, Cells, and Biobanks: Yes, There’s Still a Consent Problem,” PLoS Biology 15 (2017): e2002654.CrossRefGoogle ScholarPubMed
Spector-Bagdady, K. et al., “Encouraging Participation and Transparency in Biobank Research,” Health Affairs 37 (2018): 1313–1320.CrossRefGoogle ScholarPubMed
Critchley et al., “Identifying the Nature and Extent of Public and Donor Concern About the Commercialization of Biobanks for Genomic Research,” European Journal of Human Genetics 29 (2021): 503-511; Critchley, C., Nicol, D., and Otlowski, M., “The Impact of Commercialisation and Genetic Data Sharing Arrangements on Public Trust and the Intention to Participate in Biobank Research,” Public Health Genomics 18 (2015): 160–172; R. De Vries et al., “Biobanks and the Moral Concerns of Donors: A Democratic Deliberation,” Qualitative Health Research 29 (2019): 1942-1953; K. O’Doherty and M. Burgess, “Engaging the Public on Biobanks: Outcomes of the BC Biobank Deliberation,” Public Health Genomics 12 (2009): 203-215.CrossRefGoogle Scholar
Kim, J. et al., “Patient Perspectives About Decisions to Share Medical Data and Biospecimens for Research,” JAMA Network Open 2 (2019): e199550; M.M. Mello et al., “Clinical Trial Participants’ Views of the Risks and Benefits of Data Sharing,” NEJM 378 (2018): 2202-2211.CrossRefGoogle ScholarPubMed
Peppercorn, J. et al., “Patient Preferences for Use of Archived Biospecimens from Oncology Trials When Adequacy of Informed Consent Is Unclear,” The Oncologist 24 (2019): 1–9.Google Scholar
Evans, B.E. and Meslin, E.M., “Biospecimens, Commercial Research, and the Elusive Public Benefit Standard,” in Specimen Science: Ethics and Policy Implications, eds. Lynch, H. F., Beirer, B. E., Cohen, I. G., and Rivera, S. M. (MIT Press, 2017): 108–123; Also see M.P. Tully, L. Hassan, M. Oswald, and J. Ainsworth “Commercial Use of Health Data — A Public ‘Trial’ by Citizens’ Jury,” Learning Health Systems 3 (2019): e10200.Google Scholar
Garrett et al., “Standard Versus Simplified Consent Materials for Biobank Participation: Differences in Patient Knowledge and Trial Accrual,” Journal of Empirical Research on Human Research Ethics 12 (2017): 326–334.CrossRefGoogle Scholar
Kasperbauer, T.J., Schmidt, K.K., Thomas, A., Perkins, S. M., and Schwartz, P.H., “Incorporating Biobank Consent into a Healthcare Setting: Challenges for Patient Understanding,” AJOB Empirical Bioethics 12 (2021): 113–122Also see Beskow et al., “Improving Biobank Consent Comprehension: A National Randomized Survey to Assess the Effect of a Simplified Form and Review/retest Intervention,” Genetics in Medicine 19 (2017): 505-512.CrossRefGoogle ScholarPubMed
Spector-Bagdady, K., Hutchinson, R., O’Brien Kaleba, E., and Kheterpal, S., “Sharing Health Data and Biospecimens with Industry — A Principle-Driven, Practical Approach,” NEJM 382 (2020): 2072–2075.CrossRefGoogle ScholarPubMed